Mizuho Cuts Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $1.50

Adaptimmune Therapeutics (NASDAQ:ADAP) had its target price decreased by Mizuho from $3.00 to $1.50 in a research note published on Wednesday morning,Benzinga reports. Mizuho currently has an outperform rating on the biotechnology company’s stock.

Several other research analysts have also recently issued reports on ADAP. HC Wainwright cut their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Thursday, November 14th. Guggenheim dropped their price target on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Finally, StockNews.com cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Adaptimmune Therapeutics presently has a consensus rating of “Buy” and an average price target of $2.79.

Adaptimmune Therapeutics Trading Down 0.6 %

Shares of ADAP stock opened at $0.72 on Wednesday. The business has a 50-day moving average of $0.81 and a 200 day moving average of $1.00. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. Adaptimmune Therapeutics has a 1-year low of $0.43 and a 1-year high of $2.05. The stock has a market capitalization of $184.41 million, a PE ratio of -3.28 and a beta of 2.26.

Hedge Funds Weigh In On Adaptimmune Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ADAP. Long Focus Capital Management LLC increased its position in shares of Adaptimmune Therapeutics by 15.6% during the second quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock valued at $12,037,000 after buying an additional 1,662,184 shares during the period. Baillie Gifford & Co. boosted its position in Adaptimmune Therapeutics by 10.7% during the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock valued at $15,944,000 after acquiring an additional 1,626,657 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Adaptimmune Therapeutics during the 3rd quarter valued at approximately $95,000. Renaissance Technologies LLC grew its holdings in shares of Adaptimmune Therapeutics by 28.3% during the 2nd quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock worth $1,742,000 after acquiring an additional 394,566 shares during the period. Finally, Vontobel Holding Ltd. raised its position in shares of Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 30,000 shares in the last quarter. Institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.